VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$215.01

Market cap

$55.66B

P/E Ratio

20.21

Dividend/share

N/A

EPS

$10.64

Enterprise value

$50.25B

Sector: Healthcare
Industry: Biotechnology

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights

Vertex Pharmaceuticals's net income has surged by 83% YoY
The EPS has surged by 82% year-on-year
VRTX's debt has soared by 69% YoY

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
258.87M
Market cap
$55.66B
Enterprise value
$50.25B
Valuations
Price to earnings (P/E)
20.21
Price to book (P/B)
6.22
Price to sales (P/S)
8.69
EV/EBIT
15.05
EV/EBITDA
14.56
EV/Sales
7.83
Earnings
Revenue
$6.41B
EBIT
$3.34B
EBITDA
$3.45B
Free cash flow
$3.05B
Per share
EPS
$10.64
Free cash flow per share
$11.75
Book value per share
$34.54
Revenue per share
$24.73
TBVPS
$41.3
Balance sheet
Total assets
$12.12B
Total liabilities
$3.13B
Debt
$898.8M
Equity
$8.98B
Working capital
$6.6B
Liquidity
Debt to equity
0.1
Current ratio
4.39
Quick ratio
4.06
Net debt/EBITDA
-1.57
Margins
EBITDA margin
53.8%
Gross margin
88.1%
Net margin
43.1%
Operating margin
47.3%
Efficiency
Return on assets
24.3%
Return on equity
33.2%
Return on invested capital
106.6%
Return on capital employed
32.8%
Return on sales
52.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.87%
1 week
-1.46%
1 month
1.08%
1 year
-20.37%
YTD
-9.03%
QTD
0.06%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$6.41B
Gross profit
$5.65B
Operating income
$3.03B
Net income
$2.76B
Gross margin
88.1%
Net margin
43.1%
The operating income has surged by 84% year-on-year and by 6% since the previous quarter
Vertex Pharmaceuticals's net income has surged by 83% YoY
The operating margin has increased by 38% YoY and by 2.4% QoQ
VRTX's net margin is up by 37% YoY

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
20.21
P/B
6.22
P/S
8.69
EV/EBIT
15.05
EV/EBITDA
14.56
EV/Sales
7.83
The EPS has surged by 82% year-on-year
The price to earnings (P/E) is 72% less than the 5-year quarterly average of 73.2 and 23% less than the last 4 quarters average of 26.3
The stock's price to book (P/B) is 55% less than its 5-year quarterly average of 13.7 and 22% less than its last 4 quarters average of 8.0
The equity has grown by 39% YoY and by 3.4% from the previous quarter
The price to sales (P/S) is 36% less than the 5-year quarterly average of 13.6 and 22% less than the last 4 quarters average of 11.1
VRTX's revenue is up by 33% YoY and by 3.4% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has surged by 77% year-on-year
The return on sales has increased by 40% year-on-year
VRTX's return on assets is up by 28% year-on-year but it is down by 5% since the previous quarter
The return on equity has grown by 26% year-on-year but it has declined by 6% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 36% YoY and by 3.1% QoQ
The total liabilities has increased by 29% YoY and by 2.3% QoQ
VRTX's debt is 90% lower than its equity
VRTX's debt has soared by 69% YoY
The equity has grown by 39% YoY and by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.